IDEXX Laboratories, Inc. $IDXX Position Increased by Swiss National Bank

Swiss National Bank increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.9% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 234,380 shares of the company’s stock after acquiring an additional 15,200 shares during the quarter. Swiss National Bank owned approximately 0.30% of IDEXX Laboratories worth $131,696,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Harbour Investments Inc. raised its stake in IDEXX Laboratories by 13.3% during the 4th quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock valued at $92,000 after purchasing an additional 16 shares during the period. CWA Asset Management Group LLC lifted its holdings in shares of IDEXX Laboratories by 3.5% in the fourth quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock valued at $344,000 after purchasing an additional 17 shares in the last quarter. Rockland Trust Co. boosted its position in shares of IDEXX Laboratories by 4.4% in the fourth quarter. Rockland Trust Co. now owns 425 shares of the company’s stock worth $288,000 after buying an additional 18 shares during the period. Prime Capital Investment Advisors LLC boosted its position in shares of IDEXX Laboratories by 0.5% in the fourth quarter. Prime Capital Investment Advisors LLC now owns 3,923 shares of the company’s stock worth $2,654,000 after buying an additional 18 shares during the period. Finally, Pinnacle Associates Ltd. grew its holdings in shares of IDEXX Laboratories by 1.5% during the fourth quarter. Pinnacle Associates Ltd. now owns 1,227 shares of the company’s stock valued at $830,000 after buying an additional 18 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on IDXX. Citigroup began coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. UBS Group cut their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Finally, Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Six investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Trading Down 0.6%

Shares of IDXX stock opened at $563.81 on Tuesday. IDEXX Laboratories, Inc. has a 12 month low of $513.02 and a 12 month high of $769.98. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The business’s 50 day moving average is $555.13 and its two-hundred day moving average is $598.49. The company has a market cap of $44.47 billion, a PE ratio of 41.52, a price-to-earnings-growth ratio of 3.10 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping the consensus estimate of $3.41 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business’s quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter last year, the firm posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.